Acrivon Therapeutics, Inc. Common Stock
ACRV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $1,006 | $536 | $0 | $0 |
| Gross Profit | -$1,006 | -$536 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $63,992 | $45,488 | $23,949 | $13,718 |
| G&A Expenses | $25,207 | $21,079 | $8,708 | $2,466 |
| SG&A Expenses | $25,207 | $21,213 | $8,708 | $2,466 |
| Sales & Mktg Exp. | $0 | $134 | $0 | $0 |
| Other Operating Expenses | -$1,006 | $0 | $0 | $0 |
| Operating Expenses | $88,193 | $66,701 | $32,657 | $16,184 |
| Operating Income | -$89,199 | -$67,237 | -$32,657 | -$16,184 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $8,643 | $6,849 | $1,490 | -$59 |
| Pre-Tax Income | -$80,556 | -$60,388 | -$31,167 | -$16,243 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$80,556 | -$60,388 | -$31,167 | -$16,243 |
| % Margin | – | – | – | – |
| EPS | -2.1 | -2.74 | -1.42 | -1.26 |
| % Growth | 23.4% | -93% | -12.7% | – |
| EPS Diluted | -2.1 | -2.74 | -1.42 | -1.26 |
| Weighted Avg Shares Out | 38,296 | 22,078 | 21,921 | 12,910 |
| Weighted Avg Shares Out Dil | 38,296 | 22,078 | 21,921 | 12,910 |
| Supplemental Information | – | – | – | – |
| Interest Income | $9,201 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,006 | $536 | $364 | $37 |
| EBITDA | -$79,550 | -$59,852 | -$32,293 | -$16,147 |
| % Margin | – | – | – | – |